Survival of patients with prostate cancer

Authors

  • Fabienne Camilo da Silveira Pirajá Universidade Federal do Piauí - UFPI
  • Rafael Bandeira Lages Universidade Federal do Piauí - UFPI
  • Uylma Assunção Costa Universidade Federal do Piauí - UFPI
  • João Batista Mendes Teles Universidade Federal do Piauí - UFPI
  • Viriato Campelo Universidade Federal do Piauí - UFPI

DOI:

https://doi.org/10.5020/2617

Keywords:

Prostatic Neoplasms, Survival Analysis, Prostatic Diseases.

Abstract

Objective: To analyze the survival after five years among patients treated of prostate cancer at Hospital São Marcos. Methods: A descriptive population-based epidemiological study performed in Teresina-PI, evaluating a hospital cohort consisting of 71 patients of Hospital São Marcos, enrolled in Hospital Cancer Registry (HCR) from 2000 to 2001, under ICD10 -C61. The variables considered in the evaluation of survival were: age group, tumor staging and skin color. The Kaplan-Meier method was used in the calculation of survival functions in five years and the Kruskal-Wallis test in comparison between variables. Results: The specific survival rate for prostate cancer was of 78.5% in five years. The death risk in this study increased with age and advanced stage at diagnosis (aged 80 or above = 60%; and stage IV = 63%). The Kruskal-Wallis test showed no statistically significant variation between groups. Conclusion: The age and advanced stage at diagnosis decreased patients’ survival.

Downloads

Download data is not yet available.

References

Ministério da Saúde (BR), Instituto Nacional de Câncer. A situação do câncer no Brasil. Rio de Janeiro:INCA; 2006.

World Health Organization - WHO. Are the number of câncer cases increasing or decreasing in the world?Disponível em: http://www.who.int/features/qa/15/en/index.html. Acessado em 06 de setembro de 2001.

Tonon TCA, Schoffen JPF. Câncer de próstata:uma revisão da literatura. Rev Saúde Pesquisa.2009;2(3):403-10.

Ministério da Saúde (BR), Instituto Nacional de Câncer.Estimativa 2010: incidência do câncer no Brasil. Rio de Janeiro: INCA; 2009.

Bailar III JC, Gornik HL. Cancer undefeated. N Engl J Med. 1997;336:1569-74.

Wünsch Filho V, Moncau JE. Mortalidade por câncer no Brasil 1980-1995: padrões regionais e tendências temporais. Rev Assoc Med Bras. 2002; 48(3):250-7.

Bouchardy C, Fioretta G, Rapiti E, Verkooijen HM,Rapin CH, Schmidlin F, et al. Recent trends in prostate cancer mortality show a continuous decrease in several countries. Int J Cancer. 2008;123(2):421-9.

Fonseca LAM, Eluf Neto J, Wünsch Filho V.Tendências da mortalidade por câncer nas capitais dos estados do Brasil, 1980-2004. Rev Assoc Med Bras. 2010;56(3):309-12.

Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 1999;83(1):18-29.

Laurenti R, Jorge MHPM, Gotlieb SLD. Perfil epidemiológico da morbi-mortalidade masculina.Ciênc Saúde Coletiva. 2005;10(1):35-46.

Baade PD, Coory MD, Aitken JF. International trends in prostate-cancer mortality: the decrease is continuing and spreading. Cancer Causes Control. 2004;15(3):237-41.

Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC, et al. Cancer surveillance series:interpreting trends in prostate cancer-part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst. 1999;91(12):1017-24.

Guerra MR, Gallo CVM, Mendonça GAS. Risco de câncer no Brasil: tendências e estudos epidemiológicos mais recentes. Rev Brasi Cancerol. 2005;51(3):227-234.

Quinn M, Babb, P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality.Part II: individual countries. BJU Int. 2002;90(2):174-84.

Neal DE, Donovan JL, Martin RM, Hamdy FC.Screening for prostate cancer remains controversial.Lancet. 2009;374(9700):1482-3.

Schroder FH, Hugosson J, Roobol MJ. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320–28.

Gonçalves IR, Padovani C, Popim RC. Caracterização epidemiológica e demográfica de homens com câncer de próstata. Ciênc Saúde Coletiva 2008;13(4):1337-42.

Vercelli M, Quaglia A, Marani E, Parodi S. Prostate cancer incidence and mortality trends among elderly and adult Europeans. Crit Rev Oncol Hematol.2000;35(2):133-44.

Migowski A, Silva GA. Sobrevida e fatores prognósticos de pacientes com câncer de próstata clinicamente localizado. Rev Saúde Pública. 2010;44(2):344-52.

Dall’oglio MF, Crippa A, Antunes AA, Nesrallah LJ,Leite KR, Srougi M.. Survival of patients with prostate cancer and normal PSA levels treated by radical prostatectomy. Int Braz J Urol. 2005;31(3):222-7.

Stanford JL, Stephenson RA, Coyle LM, Cerhan J, Correa R, Eley JW, et al. Prostate Cancer Trends 1973-1995, SEER Program, National Cancer Institute.Bethesda, MD; 1999.

Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, et al. Cancer survival in five continents: a worldwide population-based study(CONCORD). Lancet Oncol. 2008;9(8):730-56.

Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality.Rev Int J Cancer. 2000;85:60-67.

Moul, J. W., Douglas, T. H., McCarthy, W. F. and McLeod, D. G. Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. J Urol. 1996;155(5):1667-73.

Roach M 3rd, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Grignon D. Race and survival of men treated for prostate cancer on radiation therapy oncology group phase III randomized trials. J Urol. 2003;169(1):245-50.

Chu KC, Tarone RE, Freeman HP. Trends in prostate cancer mortality among black men and white men in the United States. Cancer. 2003;97(6):1507-16.

Downloads

Published

2013-08-09

How to Cite

Pirajá, F. C. da S., Lages, R. B., Costa, U. A., Teles, J. B. M., & Campelo, V. (2013). Survival of patients with prostate cancer. Brazilian Journal in Health Promotion, 26(1), 44–49. https://doi.org/10.5020/2617

Issue

Vol. 26 No. 1 (2013)

Section

Original Articles

License

Submitted manuscripts must be exclusively destined to RBPS and are not allowed to be submitted to another journal. When submitting the manuscript, authors must include the Declaration of Responsibility and Assignment of Copyright signed by all authors. The document must describe individual contribution to the preparation of the manuscript and be submitted in a pdf format. The author may deposit the final version of the article with post-print peer review in any repository or website under the Creative Commons Attribution 4.0 International License.